SynthesisJournal of cardiovascular translational research2026
Fibro-Inflammatory Signaling, Fibrosis, and Microvascular Ischemia as Convergent Translational Substrates of Sudden Cardiac Death in Hypertrophic Cardiomyopathy: A Systematic Review.
Synthesis in Journal of cardiovascular translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertrophic cardiomyopathy (HCM) remains an important cause of sudden cardiac death (SCD), but the biological determinants of ventricular arrhythmic vulnerability remain incompletely defined. This systematic translational review examined whether fibro-inflammatory signaling, fibrotic remodeling, and microvascular ischemia represent convergent components of the arrhythmogenic substrate in HCM. MEDLINE/PubMed, Embase, Web of Science Core Collection, and Cochrane Library were searched from inception to January 2026. Of 167 records, 37 full-text reports were assessed and 11 studies included. Fibrosis emerged as the most clinically mature substrate marker, while microvascular ischemia appeared to amplify electrical instability, particularly in remodeled myocardium. Molecular and tissue studies suggested upstream fibro-inflammatory programs involving activated fibroblasts, extracellular matrix dysregulation, SMAD/TGF-beta signaling, CRLF1/LIFR-JAK-STAT signaling, and altered multicellular communication. Overall, the evidence supports an integrated mechanism-to-substrate model, but prospective outcome-validated studies are needed before these biological layers can refine SCD risk stratification beyond established clinical and imaging markers in contemporary HCM practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.